TickerFacts.

CytomX Therapeutics, Inc. (CTMX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Older than the company's other figures. The latest EBITDA is for the year ended 2018-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$75.99M
Year ended 2018-12-31
2013-12-31: -$14.30M2014-12-31: -$28.98M2015-12-31: -$32.00M2016-12-31: -$57.85M2017-12-31: -$44.61M2018-12-31: -$75.99M-$75.99M
2013-12-31 EBITDA (USD) 2018-12-31
Period endedEBITDAChange YoYSource filing
2018-12-31-$75.99Mn/m2021-02-24, From 2018-01-01
2017-12-31-$44.61Mn/m2020-02-27, From 2017-01-01
2016-12-31-$57.85Mn/m2019-02-27, From 2016-01-01
2015-12-31-$32.00Mn/m2018-03-07, From 2015-01-01
2014-12-31-$28.98Mn/m2017-03-02, From 2014-01-01
2013-12-31-$14.30Mn/a2016-03-07, From 2013-01-01